8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 6, 2018)

Filed November 6, 2018For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 5, 2018, to announce its financial and operating results for the third quarter ended September 30, 2018. The press release, furnished as an exhibit, provides details on the company's performance during the period. Investors should review this press release for comprehensive updates on revenue, profitability, and key operational metrics impacting the company's business. This filing serves as the primary channel for disseminating the latest quarterly performance. While the 8-K itself is brief, it directs investors to the accompanying press release (Exhibit 99.1) which contains the substantive financial and operational information. Therefore, the investor focus should be on the details within that press release to understand Regeneron's recent financial health and strategic developments.

Key Highlights

  • 1Regeneron Pharmaceuticals announced its third quarter 2018 financial and operating results.
  • 2The 8-K filing includes a press release dated November 6, 2018, detailing the Q3 2018 performance.
  • 3Investors are directed to Exhibit 99.1 (the press release) for the specific financial and operational data.
  • 4The filing is considered informational, with the press release being the source of key performance indicators.
  • 5No material new events beyond the Q3 earnings announcement are detailed in the 8-K itself.

Frequently Asked Questions

The main purpose of this 8-K filing is to announce and provide access to Regeneron Pharmaceuticals' financial and operating results for the third quarter ended September 30, 2018, through an accompanying press release.

The actual financial results and operational details for the third quarter are contained within the press release dated November 6, 2018, which is included as Exhibit 99.1 to this 8-K filing.

This specific 8-K filing primarily serves to report the quarterly financial results. It does not, in itself, detail new business developments or significant corporate events beyond the earnings announcement. Investors should refer to the attached press release for performance metrics.

According to the filing, the information included or incorporated in Item 2.02 and Exhibit 99.1 shall not be deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference into any filings under the Securities Act of 1933, unless expressly stated otherwise in a future filing.